Opioids such as morphine produce analgesia via mu opioid receptor (MOR), but opioid receptor signaling is not fully understood. Here we report that morphine analgesia and MOR signaling require neuronal Programmed cell death protein-1 (PD-1). We found that morphine-induced antinociception following systemic or intrathecal injection was compromised in Pd1 −/− mice.
Programmed cell death ligand-1 (PD-L1) is an immune checkpoint inhibitor and suppresses immunity through PD-1 receptor expressed on immune cells [1] [2] [3] . Emerging immune therapies using anti-PD1 and anti-PD-L1 monoclonal antibodies have shown success in treating various cancers including melanoma by immune activation [4] [5] [6] . However, PD-1 signaling in neurons are largely unknown. We recently reported that primary sensory neurons of dorsal root ganglion (DRG) express PD-1 receptor, and activation of PD-1 by PD-L1 inhibits neuronal excitability and pain 7 . Notably, PD-L1 is also produced by non-malignant tissues including DRG and spinal cord 7 , implicating a physiological role of PD-L1. Opioids such as morphine produce analgesia via mu opioid receptor (MOR) 8 , which is expressed in the central nervous system (brain and spinal cord) and peripheral nervous system (DRG and nerves) [9] [10] [11] [12] . MOR mediates both analgesic and reward effects of opioids, such as morphine 8, 13 . This study was undertaken to investigate the interactions between PD-1 and MOR, two inhibitory and analgesic receptors in the peripheral and central nervous system.
We first examined whether morphine analgesia would be altered in Pd1 knockout (KO, Pd1 −/− ) mice after systemic injection (1, 3, and 10 mg/kg, s.c) using both tail-flick test and hot plate test. Tailflick test in wild-type (WT) mice revealed a rapid (<0.5 h) and dose-dependent increase in tail-flick latency (TFL) for > 3 h after morphine treatment ( Fig. 1A; and fig. S1A ). Notably, this antinociception was compromised in KO mice, showing a shorter duration of < 3 h. Area-under-the-curve (AUC) analysis showed a 40% reduction in morphine analgesia at the dose of 10 mg/kg in KO mice, as compared to WT mice ( Fig. 1A; and fig. S1A-C). Hot plate test also showed an impairment of morphine analgesia in KO mice, with a 61% reduction in AUC ( Fig. 1B; and fig. S1D-F).
Next, we assessed the central mechanism of morphine analgesia in WT and Pd1 −/− mice. Spinal injection of morphine via intrathecal route (2 nmol, i.t.) elicited marked antinociception in tail-flick and hot plate tests in WT mice; but this spinal analgesic action of morphine was also compromised in Pd1 −/− mice (Fig. 1, C Opioid is a mainstay treatment for cancer pain, which often becomes unbearable after tumor metastasis to bone tissue 15 . We assessed whether morphine would attenuate cancer pain in WT and KO mice in bone cancer pain 16 . Inoculation of Lewis lung cancer cells into tibia resulted in severe cancer pain, as indicated by reductions in mechanical and thermal pain thresholds. Systemic morphine completely reversed tumor-induced mechanical allodynia and heat hyperalgesia in WT mice ( Fig. 1F ). Remarkably, the anti-allodynic and anti-hyperalgesic effects of morphine were largely abolished in KO mice ( Fig. 1F ).
Next, we tested whether loss of morphine analgesia in Pd1 −/− mice could be recapitulated by treatment of Nivolumab, a human anti-PD-1 monoclonal antibody that is also able to evoke allodynia in naive mice 7 . Tail-flick and hot plate tests showed that the antinociception induced by systemic morphine To determine the mechanisms by which PD-1 regulates opioid analgesia, we examined the PD-1/MOR interactions at cellular level. In DRG, MOR is mainly expressed by small-diameter nociceptive neurons as well as some medium-diameter neurons 9, 12, 17 . We assessed colocalization of Pd1 and Oprm1 mRNA expression in mouse DRG using a sensitive RNAscope assay. We observed high level of colocalization of Pd1 and Oprm1 in DRG neurons (Fig. 3, A and B ). To determine the mRNA expression levels of Pd1 and Oprm1 in individual DRG neurons, we quantified the number of fluorescence-labeled puncta in positive neurons. We found that around 45% neurons express Pd1 mRNA, 40% neurons express Oprm1 mRNA, and 30% DRG neurons expressed both mRNAs ( Fig. 3C ). Among the Pd1 mRNA + cells, around 60% of them co-expressed Oprm1 (Fig. 3C ).
Immunohistochemistry also showed high degree of co-localization of PD-1 and MOR immunoreactivity (IR) in DRG neurons ( Fig. 3D ). Especially, the co-localization was observed on the cell surface of small-diameter DRG neurons (Fig. 3D ). The specificity of PD-1-IR was confirmed by the lack of staining after the blocking peptide treatment ( Fig. 3D ) and in KO mice 7 . Furthermore, we observed co- Since anti-PD-1 immunotherapy has been extensively tested in humans, we also examined possible PD-1 and MOR interaction in human DRG and nerve tissues. We previously showed the presence of PD- S5c ). Collectively, it is suggested that PD-1 may also interact with MOR in human nerve tissue.
One mechanism for opioid to inhibit pain transmission is to suppress calcium channels in primary afferent neurons 18 . We recorded calcium currents in dissociated small-diameter DRG neurons (<25 m) using whole-cell patch clamp 18 . Morphine (10 M) produced a 35% reduction in calcium currents in WT DRG neurons, but this inhibition was blunted in Pd1-deficient DRG neurons (Fig. 3 , G and H). This result suggests that PD-1 regulates morphine analgesia in part through calcium channels.
The second mechanism for opioid analgesia is to inhibit neurotransmitter release and nociceptive synaptic transmission via presynaptic regulation in the spinal cord dorsal horn (SDH) [19] [20] [21] . Double staining revealed co-localization of PD-1 and MOR IR in SDH axons and axonal terminals ( fig. S7A ). PD-1 expression by SDH presynaptic terminals was also confirmed by its colocalization with CGRP, a neuropeptide derived from primary afferents ( Fig. S7B ). We prepared spinal cord slices to record spontaneous excitatory post-synaptic currents (sEPSCs) in out lamina II (IIo) neurons, which are predominantly excitatory and form a nociceptive circuit with primary C-afferents and lamina I project neurons 22, 23 . Bath perfusion of morphine (10 M) in spinal cord slices of WT mice resulted in a marked inhibition of sEPSC frequency (44.8% inhibition, Fig. 4 , A-E). However, in Pd1-deficient SDH neurons, this inhibition was significantly lower (22.7%, P = 0.0068, two-tailed t-test, KO vs. WT mice, Fig. 4E ).
Morphine (10 M) also caused a mild inhibition of sEPSC amplitude (10.7%) in WT mice (P = 0.0068, two-tailed t-test) and had no inhibition of the sEPSC amplitude in KO mice (P = 0.1272, paired two-tailed t-test). No significant difference was observed in the sEPSC amplitude between WT and KO mice after morphine treatment (n=13-14 neurons, P= 0.2692, paired two-tailed t-test, Fig. 4E ). A dose-response analysis showed that morphine suppressed sEPSC frequency at IC50 = 1.07 μM in WT mice, but the IC50 value was increased to 15. PD-L1 is a major ligand of PD-1 and produces antinociception in mouse models of pathological pain 7 . We investigated whether PD-L1 would modulate synaptic transmission via PD-1 in SDH neurons.
Dose response analysis showed that the IC50 for PD-L1 and morphine to inhibit sEPSC frequency is 0.60 nM and 1.7 µM, respectively ( fig. S9A,B ), suggesting that PD-L1 is 1700 times more potent than morphine. As expected, the effects of PD-L1 on sEPSCs were blunted in Pd1-deficient neurons ( fig. S9C ).
Notably, in naïve animals, Pd1 deficiency lead to an increase in sEPSC frequency but not amplitude ( fig.   S9D ), indicating that PD-1 is an endogenous negative regulator of synaptic transmission.
The third mechanism of opioid analgesia is to regulate potassium channels to generate outward currents in neurons 24 . Morphine (10 M) evoked outward currents in 36.7% (5/14) SDH neurons of WT mice, and the average amplitude of outward currents was 15.8 ± 1.5 pA. In contrast, morphine-evoked outward currents were significantly smaller in KO mice (7.8 ± 1.8 pA; P = 0.0104, unpaired two-tailed ttest, vs. WT), despite similar response rate of 30.7% (4/13) (fig. S10A-C). PD-L1 also evoked dosedependent outward currents (5-18 pA) in 20-50% SDH neurons, and these outward currents were abolished in KO mice ( fig. S10D,E) .
As expected, Nivolumab also blocked the morphine's effects on SDH neurons in WT mice.
Perfusion of spinal cord slices with Nivolumab at a very low concentration (100 ng/ml, i.e. 0.7 nM) significantly reduced the morphine's inhibition of sEPSC frequency (P < 0.001, compared with human IgG4 control, Fig. 4 , F-H). Nivolumab at this low concentration (0.7 nM) did not affect sEPSC frequency, but increased sEPSC frequency at high concentrations (2.1 and 10.5 nM, fig. S11A-F) . Neither did the control IgG4 affect the morphine's inhibition of sEPSC (Fig. 4H ). Nivolumab also suppressed morphine's inhibition of sEPSCs amplitude (Fig. 4H ).
Finally, we assessed whether PD-L1 and morphine would produce additive or synergistic actions in inhibiting synaptic transmission and pain. At very low concentrations, PD-L1 (0.075 nM) and morphine (0.01 M) each produced mild inhibition of sEPSC frequency (5% and 8%, respectively), but coapplication of PD-L1 and morphine at these low concentrations produced a much greater inhibition (40%) of sEPSCs, suggesting a synergistic effect of these two compounds at low concentrations (Fig. 4, I and J) .
This synergistic action of morphine and PD-L1 was also evident in behavioral testing. Intrathecal PD-L1 (0.075 nmol) alone failed to produce any analgesia, and intrathecal morphine (0.75 nmol) only produce very mild and transient analgesia, but intrathecal co-application of PD-L1 and morphine at these low doses produced a much greater analgesia, indicating a synergistic analgesic effect ( Fig. 4K and fig. S12 ).
In summary, we have demonstrated that the morphine's key analgesic actions, such as antinociception in tail-flick and hot plate tests, anti-hyperalgesic and anti-allodynic effects in bone cancer pain, suppression of calcium currents in DRG neurons, as well as inhibition of sEPSCs and induction of outward currents in SDH neurons are all abrogated in Pd1 −/− mice. Co-IP suggested that PD-1 may interact with MOR in mouse DRG neurons and human nerve axons, although future studies are required to determine the details of the interaction. The functional interactions only occur between PD-1 with MOR, but not with DOR or KOR. Importantly, the defects in morphine signaling in Pd1 −/− mice can be recapitulated by Nivolumab treatment in adult mice. In Pd1-deficinet mice, morphine's analgesia in bone cancer pain is largely impaired. Our findings have clinical implication, because 1) Nivolumab has been approved for treating various cancers and 2) opioids are mainstay treatments for cancer pain and peripheral analgesic actions of opioids are well appreciated 10, 12, 25, 26 . Thus, anti-PD-1 immune therapy may interfere opioid analgesia in cancer patients via disrupting the PD-1-MOR interaction in the peripheral nerve and DRG tissue. Opioid receptor has also been implicated in placebo analgesia 27 , and it will be interesting to know if immune therapy would interrupt this unique type of analgesia. On the other hand, PD-L1 might be used to treat clinical pain and enhance opioid analgesia in cancer and non-cancer patients. (7)(7) (13)(8) (7)(7) (13)(8) (8)(7) (7)(7) (8)(7) (7)(7) 
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